Mechanisms of resistance to telithromycin in Streptococcus pneumoniae

被引:18
作者
Hisanaga, T [1 ]
Hoban, DJ
Zhanel, GG
机构
[1] Univ Manitoba, Fac Med, Dept Med Microbiol, Winnipeg, MB, Canada
[2] Hlth Sci Ctr, Dept Clin Microbiol, Winnipeg, MB R3A 1R9, Canada
[3] Ctr Hlth Sci, Dept Med, Winnipeg, MB R3A 1R9, Canada
关键词
mutations; 23S rRNA; mef(A); erm(B);
D O I
10.1093/jac/dki249
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Reports of ketolide resistance remain scarce, however, a few laboratory-derived and clinical isolates of resistant Streptococcus pneumoniae have been documented. Mutations in key telithromycin-binding sites such as domains II and V of the 23S rRNA and ribosomal proteins L4 and L22, as well as mutations of the resistance determinant erm(B) are associated with elevated telithromycin MICs. Mutations in the secondary binding site of domain II coupled with ribosomal methylation may have serious resistance consequences should the domain II binding site be lost. Although ketolides are purported to maintain excellent activity against efflux-positive isolates, laboratory-derived telithromycin-resistant strains have been generated. As telithromycin usage increases, ketolide-resistant isolates of S. pneumoniae may well increase.
引用
收藏
页码:447 / 450
页数:4
相关论文
共 22 条
[1]   Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae [J].
Canu, A ;
Malbruny, B ;
Coquemont, M ;
Davies, TA ;
Appelbaum, PC ;
Leclercq, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :125-131
[2]   Studies of the novel ketolide ABT-773:: Transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae [J].
Capobianco, JO ;
Cao, ZS ;
Shortridge, VD ;
Ma, ZK ;
Flamm, RK ;
Zhong, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1562-1567
[3]  
CORNAGLIA G, 2002, 12 EUR C CLIN MICR I
[4]   In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae [J].
Davies, TA ;
Dewasse, BE ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :414-417
[5]   Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: Molecular mechanisms and resistance phenotypes [J].
Edelstein, PH .
CLINICAL INFECTIOUS DISEASES, 2004, 38 :S322-S327
[6]   In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations [J].
Farrell, DJ ;
Morrissey, I ;
Bakker, S ;
Buckridge, S ;
Felmingham, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) :3169-3171
[7]   Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003 [J].
Farrell, DJ ;
Felmingham, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (05) :1882-1884
[8]  
FARRELL DJ, 2004, 14 EUR C CLIN MICR I
[9]  
Franceschi F., 2004, Current Drug Targets - Infectious Disorders, V4, P177, DOI 10.2174/1568005043340740
[10]   Binding site of macrolide antibiotics on the ribosome: New resistance mutation identifies a specific interaction of ketolides with rRNA [J].
Garza-Ramos, G ;
Xiong, LQ ;
Zhong, P ;
Mankin, A .
JOURNAL OF BACTERIOLOGY, 2001, 183 (23) :6898-6907